Published on
Monday, November 19, 2012
There are at least 53 systemic antibiotic NCEs in
clinical development, of which 14 fall into innovative classes/mechanisms of
action, defined as compounds that are not based on chemical classes of any
antibiotics used systemically in humans. (A) Topoisomerase IIA (TOP2A) is not a
new target, but GSK2140944, a TOP2A inhibitor from GlaxoSmithKline plc
(LSE:GSK; NYSE:GSK), was included because it is not based on an already
approved antibiotic chemical class. Source: BCIQ: BioCentury Online Intelligence;
company documents; www.clinicaltrials.gov
